- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Eris Lifesciences Limited — Important, 03-12-2025: Updates
03-12-2025 | 03:56 pm
03-12-2025 | 03:56 pm
Eris plans ₹380-400 Cr capex in Diabesity & Injectables, targeting sub-1.5x Net Debt/EBITDA by Dec 2026. Expanded Biocon partnership to double Insulin capacity, projecting ₹50 Cr additional annual EBITDA. Secured first EU CDMO order for Injectables, with ₹125-150 Cr FY27 revenue visibility.
No comments yet. Be the first to comment!